MAZ-mediated N6-methyladenosine modification of ZEB1 promotes hepatocellular carcinoma progression by regulating METTL3
Our study revealed a promising clinical application of MAZ, METTL3, and ZEB1 in HCC prognosis, further suggesting that MAZ can be used as a potential molecular biomarker for HCC diagnosis and prognosis.
Authors
- Song Jin
- Xiaonian Zhu (ORCID: https://orcid.org/0009-0009-8307-1034)
- Chuanjun Zheng (ORCID: https://orcid.org/0000-0001-9404-6920)
- Zhengbao Zhang
- Ruyuan Liu
- Shengkui Tan (ORCID: https://orcid.org/0000-0002-1955-0868)
- Zhaonv Yao
- Xuefeng Guo (ORCID: https://orcid.org/0000-0001-5723-8528)
- Xu Li (ORCID: https://orcid.org/0000-0002-9401-6382)
- Di Li
Institutions
- Guilin Medical University (CN)
- Affiliated Hospital of Youjiang Medical University for Nationalities (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1186/s12967-025-06314-8
- Citations
- 5
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 4.03
Funders
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- National Natural Science Foundation of China
- Scientific Research and Technology Development Program of Guangxi